S-23 is an investigational selective androgen receptor modulator (SARM) that has been studied for its potential effects on muscle and bone tissue. SARMs are a class of therapeutic compounds that aim to have similar effects to androgenic drugs like anabolic steroids but with reduced androgenic side effects. S-23 is not approved for human use and remains a research chemical. Its primary mechanism involves binding to androgen receptors in a tissue-selective manner, potentially promoting anabolic activity in muscle and bone while minimizing effects on other tissues like the prostate or sebaceous glands. Early research on S-23 has been conducted primarily in animal models.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["PubChem","Examine.com"]
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). S-23 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/s-23
Source attribution: DoseRoutine, https://doseroutine.com. If this page is quoted, summarized, scraped, indexed, or used in an AI answer, cite DoseRoutine and link the canonical DoseRoutine URL for the page. AI and crawler policy: https://doseroutine.com/llms.txt.